Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Open Access
- 25 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (14), 3861-3866
- https://doi.org/10.1158/1078-0432.ccr-20-4592
Abstract
Few prospective studies have assessed anthracycline-associated cardiotoxicity in patients with sarcoma. We evaluated cardiotoxicity in patients with soft-tissue sarcomas administered doxorubicin in the phase III ANNOUNCE trial (NCT02451943). Patients were anthracycline-naïve adults with locally advanced or metastatic disease and left ventricular ejection fraction (LVEF) ≥50%. Patients could receive eight cycles of doxorubicin at 75 mg/m2. The cardioprotectant, dexrazoxane, was allowed at investigator discretion. Symptomatic cardiac adverse events (AEs) were recorded using Medical Dictionary for Regulatory Activities and graded using Common Terminology Criteria for Adverse Events 4.0. LVEF deterioration was measured by echocardiogram or multigated acquisition scan, defined as a decrease to 10%. A total of 504 patients received ≥1 cycles of doxorubicin [median cumulative dose, 450.3 mg/m2 (range, 72.3–634.0)]. Median follow-up of cardiac AEs was 28 weeks. Dexrazoxane was coadministered more frequently to patients receiving higher cumulative doxorubicin doses (38.6% receiving 2, 88.5% receiving 450–2, and 90% receiving ≥600 mg/m2) and did not affect treatment efficacy. LVEF deterioration was seen in 62 of 153 (40.5%) patients who received a cumulative dose 2, 82 of 159 patients (51.6%) who received 450–2, and 50 of 89 patients (56.2%) who received ≥600 mg/m2. Grade ≥3 cardiac dysfunction occurred in 2% of patients at 2, 3% at 450–450 mg/m2), with a low rate of cardiotoxicities, in the context of dexrazoxane coadministration. See related commentary by Benjamin and Minotti, p. 3809Keywords
Other Versions
Funding Information
- NIH
- NCI (P30 CA008748)
This publication has 22 references indexed in Scilit:
- Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline CardiotoxicityThe American Journal of Cardiology, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Systolic and diastolic dysfunction in long-term adult survivors of childhood cancerEuropean Journal of Cancer, 2011
- Cardioprotective interventions for cancer patients receiving anthracyclinesEmergencias, 2011
- Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityExpert Review of Cardiovascular Therapy, 2008
- Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's DiseaseJournal of Clinical Oncology, 2007
- Anthracycline cardiotoxicityExpert Opinion on Drug Safety, 2006
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979